Investing

Eli Lilly : LLY

LLY

Stock Data

$1,219.92

$4.90 (0.40%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Eli Lilly and Company is a global leader in pharmaceuticals, focusing on discovering, developing, and marketing a wide range of human medications. With a rich history dating back to 1876 and headquartered in Indianapolis, Indiana, it offers treatments for diabetes, including a comprehensive lineup of insulin products, and type 2 diabetes medications like Jardiance and Trulicity. The company also has a strong presence in oncology, rheumatoid arthritis, dermatology, mental health, and more, with notable products such as Alimta for cancer and Cymbalta for depression. Eli Lilly collaborates with various industry partners to enhance its product offerings.

Latest Activity

LLYEli Lilly

Q2 2026

Aug 5, 7:05am ET

EPS

$8.38

est $6.58+27.3%

Revenue

$22.97B

est $20.69B+11.1%

Mounjaro nearly doubled to $9.94 billion, pushing Lilly to lift full-year revenue guidance to $85 billion to $87 billion. Retatrutide's filing in early 2027 is the next catalyst.

Loading…

ShareRead more

All Eli Lilly Articles

678 Articles

Vandita Jadeja | Yesterday

Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a…

Joel South | Aug 10, 2026 at 8:00 AM EDT

3 Beaten-Down Healthcare Stocks to Buy in August

Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names…

Vandita Jadeja | Aug 6, 2026 at 11:30 AM EDT

This Will be Eli Lilly’s Price in 2027 And Morgan Stanley Agrees

Eli Lilly just posted revenue growth near 50% and crushed earnings estimates, yet the stock barely moved. There is a…

Thomas Richmond | Aug 5, 2026 at 2:59 PM EDT

Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless. Here’s What Comes Next for the $1 Trillion Drugmaker

Eli Lilly just posted numbers that stunned Wall Street, but the company's own executives admit a single bottleneck could cap…

Rich Duprey | Aug 5, 2026 at 9:50 AM EDT

GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may…

Thomas Richmond | Aug 3, 2026 at 1:17 PM EDT

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works…

Vandita Jadeja | Jul 31, 2026 at 1:30 PM EDT

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories…

Vandita Jadeja | Jul 24, 2026 at 1:30 PM EDT

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the…

Omor Ibne Ehsan | Jul 22, 2026 at 12:25 PM EDT

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly…

Danielle Liverance | Jul 22, 2026 at 6:22 AM EDT

“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits

Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body…

Vandita Jadeja | Jul 19, 2026 at 9:30 AM EDT

3 Biggest Pharma Giants: Buy, Sell or Hold?

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very…

Ian Cooper | Jul 16, 2026 at 1:53 PM EDT

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until…

Vandita Jadeja | Jul 13, 2026 at 2:00 PM EDT

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here…

David Moadel | Jul 10, 2026 at 12:04 PM EDT

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors…

Chris MacDonald | Jul 9, 2026 at 2:28 PM EDT

Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY | LLY Price Prediction) has added over the…